RedHill Biopharma holds recent Real Value of S228.9 per share. The prevailing price of the company is S252.7. At this time the company appears to be over valued. Macroaxis determines value of RedHill Biopharma from analyzing the company fundamentals such as Price to Sales of
85.02X, Current Valuation of 640M and Return On Equity of (112.59)% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
|Horizon||30 Days Login to change|
RedHill Biopharma Ltd is rated fifth in beta category among related companies. It is rated fourth in price to sales category among related companies fabricating about 566.80 of Price to Sales per Beta.
|Price to Sales ( times )|
December 18, 2018
RedHill Biopharma is not too risky asset. Calculation of real value of RedHill Biopharma is based on 2 months time horizon. Increasing RedHill Biopharma time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.